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Abstract
Background: Successful treatment of acute radiation syndromes relies on immediate supportive care. In patients with
limited hematopoietic recovery potential, hematopoietic stem cell (HSC) transplantation is the only curative treatment
option. Because of time consuming donor search and uncertain outcome we propose MSC treatment as an alternative
treatment for severely radiation-affected individuals.
Methods and Findings: Mouse mesenchymal stromal cells (mMSCs) were expanded from bone marrow, retrovirally labeled
with eGFP (bulk cultures) and cloned. Bulk and five selected clonal mMSCs populations were characterized in vitro for their
multilineage differentiation potential and phenotype showing no contamination with hematopoietic cells. Lethally
irradiated recipients were i.v. transplanted with bulk or clonal mMSCs. We found a long-term survival of recipients with fast
hematopoietic recovery after the transplantation of MSCs exclusively without support by HSCs. Quantitative PCR based
chimerism analysis detected eGFP-positive donor cells in peripheral blood immediately after injection and in lungs within
24 hours. However, no donor cells in any investigated tissue remained long-term. Despite the rapidly disappearing donor
cells, microarray and quantitative RT-PCR gene expression analysis in the bone marrow of MSC-transplanted animals
displayed enhanced regenerative features characterized by (i) decreased proinflammatory, ECM formation and adhesion
properties and (ii) boosted anti-inflammation, detoxification, cell cycle and anti-oxidative stress control as compared to HSC-
transplanted animals.
Conclusions: Our data revealed that systemically administered MSCs provoke a protective mechanism counteracting the
inflammatory events and also supporting detoxification and stress management after radiation exposure. Further our results
suggest that MSCs, their release of trophic factors and their HSC-niche modulating activity rescue endogenous
hematopoiesis thereby serving as fast and effective first-line treatment to combat radiation-induced hematopoietic failure.
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Introduction
The management of patients suffering from acute radiation
syndromes (ARS) still remains a major challenge. Survival of
radiation induced bone marrow failure depends on the dose of
radiation received and the intensity of supportive care which can
protect from otherwise lethal infection and give surviving stem cells
a chance to expand. To provide the best possible care for radiation
accident victims in acts of terrorism or catastrophic incidences,
medical countermeasures need to be made within the first few days
for optimal efficacy [1]. The ‘‘response category concept’’ proposed
by Fliedner et al [2] evaluates the radiation induced tissue damage
and rates the hematopoietic score 4-H4 (the highest score for
hematopoietic damage) as case with little probability for autologous
recovery. Combined approaches including presenting symptoms,
biomarkers and physical dosimetry are employed to categorize
affected individuals for best medical countermeasures [3].
Overall measures include supportive care, treatment with growth
factors within the first two weeks after radiation exposure, or
hematopoietic stem cell transplantation (HSCT). Since radiation
effects on blood stem cells occur at doses generally lower than on
other critical organs, the rapidly emerging changes in the peripheral
blood cell lineages dictate the treatment options. Animal and
human studies indicate that hematopoietic pluripotent stem cells
have a D0 of about 95cG as indicated by Fliedner et al [1]. D0 is the
dose increment that reduces the cell survival to 37%. In fact, total
body exposure at doses more than 7–8 Gy total body irradiation
(TBI) in human corresponds to medullar eradication. Under this
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5threshold spontaneous recovery from residual hematopoietic stem
and progenitor cells may be expected within 30–50 days but going
through cytopenic phases of granulocytic, megakaryocytic and
erythrocytic lineages. HSCT should be considered if the victim’s
HSC pool is essentially irreversibly damaged. Interestingly, even
after TBI, intrinsically radioresistant stem cells have been detected
in distinct bone marrow (BM) areas comprising a residual
hematopoietic stem and progenitor cell pool [4]. ARS does not
only imply damage to the bone marrow. In a dose-dependent
matter, it can also emerge as gastrointestinal and cerebrovascular
syndromes leading to development of multiple organ dysfunctions
[4]. Damage to the whole organism is related to a systemic
inflammatory response. Different target organs are affected due to
activation of the innate immune system, resulting in a significant
release of inflammatory cytokines [5]. The pathophysiology appears
comparable to that of acute graft-versus-host disease (GvHD)
following allogeneic stem cell transplantation where a similar
‘‘cytokine storm’’ has been observed [6]. Long-term effects of
ionizing radiation have been well documented in atomic bomb
survivors in whom persistent signs of inflammation, e.g. increased
plasma levels of tumor necrosis factor-a (TNF2-a), interferon-b,
interleukin-6, and C-reactive protein, have been reported [7].
Additionally, oxidative stress after high dose ionizing radiation has
been involved in delayed morbidity [4]. Management of ARS
therefore relies on tissue damage repair processes that might be
supported by therapies directed at mitigation of inflammation [4].
Efforts to improve outcome for affected individuals focus on the
stem cell niche. Therefore, visionary therapies should augment niche
activity to accelerate hematopoietic recovery in vivo. Several studies
have demonstrated that BM osteoblasts regulate the HSCpool size in
vivo via the Jagged1-Notch signaling pathway [1]. For example,
parathyroid hormone receptor activation can increase the number of
osteoblastic cells, resulting in Notch1-mediated expansion of HSCs
[8]. One integrative part of the BM stroma are the mesenchymal
stromal cells (MSCs), also described as osteoblastic progenitors [9].
MSCs have been proven to intervene with acute organ impairments.
Cotransplanted with HSCs, MSCs augment hematopoietic recovery
after chemo- or radiotherapy significantly decreasing the time to full
hematopoietic and particularly platelet reconstitution [10]. Addition-
ally, there is a large body of evidence for MSCs effectiveness in the
treatment of steroid resistant GvHD without any side effects even
when obtained from BM of third-party donors [11,12]. No HLA-
matching is needed between donor and recipient becauseMSCshave
been shown to be hypoimmunogenic and are not recognized by the
recipients immune system even after repeated injections [11,12].
Finally, MSCs secrete a plethora of bioactive molecules [13,14].
Among these, several essential hematopoietic growth factors
including IL6, IL11, LIF, SCF, and Flt3 ligand are produced but
also factors with immunomodulatory effects, e.g. TGF-b1, prosta-
glandin E2, indoleamine 2,3-dioxygenase, and others. [14,15].
Additionally, vascular endothelial growth factor (VEGF) secreted
by MSCs in large amounts might interfere with an early apoptotic cell
death after irradiation [4]. Therefore, MSCs might be a good
candidate for the modulation of hematopoietic niche activity.
Altogether, we assumed that MSCs with their comprehensive
trophic potential could serve as a readily available treatment
option after severe radiation exposure.
Results
MSCs promote hematopoietic recovery after lethal
irradiation
Dynamic evaluation of peripheral blood counts of animals
treated with bulk MSCs revealed similar leukocyte and thrombo-
cyte recovery as observed in recipients transplanted with HSCs
[16] reaching normalization of white blood cells after 4 weeks
(Figure 1). Seven months after transplantation, 2/3 of recipients
still were alive (Table 1) and hematologically well with a normal
distribution of peripheral blood cell (PB) populations (Table 2).
Figure 1. Mouse MSCs rescue mice after total body irradiation.
Transplantation of bulk mMSCs led to a normalization of the peripheral
white blood cell count within 4 weeks. Thrombocyte recovery needed
approx. 8 weeks for normalization. Thus, results are comparable to
blood recovery after HSC transplantation.
doi:10.1371/journal.pone.0014486.g001
Table 1. Phenotypical characterization of mMSCs and recipients’ survival rates after transplantation.
CD34 CD45 CD59 CD90 CD105 CD117 Sca-1
survival at 7 months
[%]
bulk 1.6 0.5 95.4 0.5 85.9 0.9 96.7 19/28 [67.9]
IXH8 9.8 4.1 97.4 2.7 1.6 1.5 99.2 15/17 [88.2]
IVH7 1.2 1.3 54.7 0.5 94.1 2.8 81.9 2/12 [16.7]
IXC2 0.9 2.2 79.6 1.2 94.0 1.5 90.2 3/10 [30]
VIIIE7 1.2 1.1 71.1 2.0 93.1 1.5 96.4 4/10 [40]
VF10 2.2 2.2 45.9 0.7 74.0 3.4 77.9 3/10 [30]
radiation control nd nd nd nd nd nd nd 0/15 [0]
Cultures of eGFP-transduced bulk and cloned mMSC after extended expansion were positive for CD59, CD105 and Sca-1 but negative for the hematopoietic markers
CD34, CD45, CD117 and for CD90 by flow cytometry. Clone IXH8 was different from all other cultures in its expression of CD34/CD45 and negativity of CD105 (shown in
bold italic). Transplantation with this clone resulted in the highest survival rate of the irradiated recipients, suggesting elevated CD34 and CD45 and no CD105
expressions might be a prerequisite of the high rescue capability. nd, not done.
doi:10.1371/journal.pone.0014486.t001
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integration site (IS) patterns for each single clone in vitro
(Figure 2). For mMSC clone IVH7 we identified 2 IS, for VF10
3 IS, for VIIIE7 1 IS, for IXC2 2 IS and for IXH8 1IS.
Integration sites shown twice might be due to incomplete digestion
of the genomic DNA. The thickness of the bands doesn’t resemble
minor or major integration sites but is inherent to the method.
Further analysis of single integration sites is shown in Table S1.
Transplantation of clonal mMSCs resulted in a superior survival
rate of recipients treated with clone IXH8 (88%) compared to
survival rates of approx. 30% obtained with other clones (Table 1).
No control animals without cell transplantation survived the TBI
longer than 3 weeks. Impressively, clone IXH8 morphologically
was different from all other cultures (Figure 3) without any
flattened cells and additionally showed a distinct phenotype with
increased CD34 and CD45 but no CD105 expression. All other
characteristics of this clone corresponded to the ISCT criteria [17]
(Figure 3, Table 1), questioning the relevance of CD105
expression for MSC characterization.
Transplanted donor cells are detectable short- but not
long-term
Stably integrated eGFP-sequences were used for tracing donor
cells in recipients after transplantation. Immediately after
injection, 20.2%615.7 of transfused cells could be detected in
the peripheral blood (Figure 4a). Within 24 hours, eGFP-positive
donor cells were diluted out from PB and trapped in lungs but not
in BM, spleen or liver (Figure 4a insert). At day 10 and later on, no
donor cells remained in any investigated tissue (PB, thymus, lymph
node, liver, spleen, lung, intestine, aorta/vena cava and abdominal
fat; not shown). A standard curve for eGFP-BM and assessment of
donor cells in long-term survivors (see Materials and Methods) is
shown in Figure 4b. This corresponds to results from repeated PB
flow cytometry analysis of recipients within the 7-month period
where no eGFP-positive or CD45.2 donor cells were found (not
shown). Although we transplanted male donor mMSCs into
female recipients, the Y-chromosome was not available for
chimerism analysis. Among various structural chromosomal
alterations and massive aneuploidy we surprisingly detected the
loss of the Y-chromosome in clonal mMSCs already during the in
vitro expansion period using spectral karyotyping (Figure 5).
MSCs salvage endogeneous hematopoiesis
While donor mMSCs did not home to the BM, the gene
expression profile in BM changed significantly, clustering as a
separate group compared to HSC transplanted mice or age-
matched BM (Figure 6a). Impressingly, the clustering of all genes
was done without any preselection giving rise to highly stable
clusters. A heat map using hierarchical clustering of up- and
downregulated genes in the MSC compared to the HSC groups
with p#0.01 and fold changes of $2.5 or #2.5 illustrates the
variations between the samples (Figure 6b). Successful validation of
selected genes by quantitative PCR (Table 3) emphasized the
beneficial role of mMSCs in endogenous hematopoietic reconsti-
tution (Figure 6c). Transplantation of mMSCs upregulated genes
in the BM involved in cell cycle and protection from oxidative
stress (Cdkn1a, BRPK) as well as in anti-inflammatory and
detoxification processes (Thbs2, Gstm5). In contrast, genes for
regulation of proinflammation (Klk6, Klk1b5), protein degrada-
tion (Uchl1), adhesion/matrix formation (Sykb, Emid1, Col5a3),
lipid synthesis (Gpam), and lymphoid development (Vpreb1,
Rag2) were downregulated. The downregulation of genes involved
in adhesion and matrix formation particularly suggests lower
retention of hematopoietic progenitor cells within the stroma and
higher potency to egress into the peripheral circulation.
Table 2. Peripheral blood cell populations in mMSC
transplanted animals.
lymphocytes neutrophils monocytes eosinophils
72%632 1 % 635 % 622 % 61
The distribution of white blood cells 5 months after bulk mMSC transplantation
was counted using Pappenheim-stained blood smears.
doi:10.1371/journal.pone.0014486.t002
Figure 2. Integration site pattern of clonal mMSCs. The clonal
mMSCs were investigated using LM-PCR. Each of the clones represents
a specific pattern of integration sites. Bands marked with red asterix
were subjected to sequencing for further characterization (see Table
S1). IC, internal control.
doi:10.1371/journal.pone.0014486.g002
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While lower dose radiation victims may profit from supportive
care, the situation is more serious after irradiation dose higher
than 6 Gy. The only curative treatment in these cases is the
transplantation of HSCs. However, this alternative depends on
whether a suitable donor is available and can be provided quickly.
The normal time required to find and deliver a HSC transplant
spans over weeks, a frame too long for seriously affected
individuals.
HSCs reside in close association with osteoblasts and sinusoidal
blood vessels within the bone marrow and this association
contributes to the maintenance of the HSC pool in vivo. Self-
renewal, proliferation and differentiation of HSCs are regulated
through intrinsic signals from the BM niche in which the MSCs
are a regulatory component [18,19]. We show here that lethally
irradiated mice fully reconstituted the blood system through
transplantation of mMSCs with similar kinetics as HSCs. Systemic
administration of non-clonal mMSCs resulted in long-term
survival of the majority of animals with normal blood cell
distribution. Generation and expansion of MSCs from C57BL/
6J mice is particularly difficult and time-consuming. Since it is well
known that rodent adherent BM cells might contain HSCs over
long periods caused by emperiopoiesis [20] among other
mechanisms, we formally cannot exclude a contamination of
MSC preparations with remaining HSCs. Therefore, clonal
mMSCs were evaluated for their reconstitution potential. Here,
surprisingly, one population of cloned mMSCs showed an even
better reconstituting potential than the bulk population. This clone
IXH8 was different from all other MSC cultures: a) morpholog-
ically, the clone consisted exclusively of spindle shaped cells
indicative for significantly accelerated proliferation of MSCs [21];
that was not observed in bulk and other clonal cultures, and b)
flow-cytometrically, we detected increased hematopoietic CD34
and CD45 but no CD105 expression. CD105 has been described
as a marker of proliferation and adhesion [22]. We assume that
lack of CD105 might increase survival of recipients by lowering
lung embolization. All other characteristics corresponded to the
ISCT criteria [17], questioning the relevance of CD105 expression
particularly for mMSC characterization. Likewise, over-expression
of CD105 in cultured endothelial cells has been shown to induce a
marked increase in protein levels of inflammatory eNOS [23],
suggesting an anti-inflammatory action of CD105-negative
mMSCs in our model. Surprisingly, none of the recipients
Figure 3. Differentiation potential of mMSCs. Mouse MSCs were generated from male C57BL/6J bone marrow and expanded for 9 passages.
Expanded mMSC were retrovirally transduced with eGFP (bulk) and cloned. Five clones with sufficient growth were selected and further expanded.
They differed regarding their morphology and growth pace. Cells from passages 14–16 were induced to differentiate into adipogenic, osteogenic and
chondrogenic cells. All clones and the parental bulk cells demonstrated three-lineage differentiation capability. Noninduced controls were negative
for the respective stainings (not shown).
doi:10.1371/journal.pone.0014486.g003
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fibrotic lesions in lungs as has been observed with non-clonal
cultures (Figure 7). Taking together the differences in morphology,
antigen expression and survival, we hypothesize that the
composition of the expanded mMSCs (e.g. significant amount of
nonproliferating osteoprogenitors) rather than the source of the
population (mMSC or hMSC as discussed in [24]) causes different
outcomes after transplantation.
The survival of recipient animals suggested the homing of
mMSC to the BM. We tested this hypothesis using either the Y-
chromosome of male donor cells or the stably integrated eGFP as
detection marker. Y-chromosome-based chimerism analysis in
female recipients could not detect donor cells in any investigated
tissue including PB and BM, although animals survived long-term.
Spectral karyotyping of clonal mMSCs revealed various structural
chromosomal alterations and massive aneuploidy (as did bulk
mMSCs) with loss of the Y-chromosome whereas bulk cultures of
passage13 were still Y-positive. Hence, mMSCs not only
accumulate chromosomal abnormalities during few in vitro
passages [24] but also might lose sex-specific chromosomes.
Despite this, no tumors or osseous inclusions were formed as
shown in Figure 7 and previously described by others [24,25]. We
assume that cloning of mMSCs selected defined populations which
do not contain replicative senescent cells as has been regularly
detected in bulk populations. The clonal mMSCs might not be
prone to stable lung embolization and thus do not lead to eventual
tumorous degeneration.
Quantitative PCR for stably integrated eGFP-sequences also
failed to detect any donor cells and no eGFP-positive cells were
found in PB, BM or thymus by flow-cytometry. These results
were unexpected, since forced in vitro differentiation of human
MSCs suggested a potential differentiation capability into
hematopoietic and endothelial cells, albeit to a rather low degree
(Figure S1). Although we cannot completely rule out the presence
of single donor cells in the investigated tissues below the detection
limit, hematopoietic recovery in recipients due to replenishment
with donor cells is unlikely in our setting. Additionally,
transplantation of cells with the shown high incidence of
chromosomal aberrations would in high probability result in
tumor formation. That was not the case in our recipients pointing
at limited survival of the cells in vivo. This conclusion contradicts
the results of earlier studies analyzing hematopoietic recovery
after myeloablative TBI with blood-derived mMSCs [26,27] and
showing donor characteristics in blood and BM. One fundamen-
tal difference between both cell sources is the immortalization of
cells with SV40 used in these studies, potentially altering BM
homing capability of MSCs. Therefore, our results support the
concept of impaired transplantability of expanded MSCs [28–30]
but also challenge the hypothesis of high plasticity of MSCs [31].
Our findings are in contrast to results obtained in immunode-
ficient mice and monkeys after MSC transfusion [32–34].
Francois et al. [32] detected 0.08% to 0.94% of injected human
MSCs in several tissues of NOD/SCID mice after TBI+/2 local
irradiation. In this study, quantitative distribution but no long-
term effects of hMSCs were studied. The low percentage might
question the physiological relevance of homed hMSCs for
intervention in irradiation-induced tissue damage. Recently, the
main mechanism through which MSCs counteract global
inflammation in sepsis has been attributed to reprogramming of
macrophages [35]. This mechanism could be active also in ARS
where TNF-a activated MSCs release prostaglandin E2 that acts
on the macrophages through the prostaglandin EP2 and EP4
receptors and induces IL-10 secretion. It well might be that,
based on this mechanism, the direct injection of hMSCs into the
humerus of non-human primates as a single treatment [33] failed
to detect any beneficial long-term effect of stromal cells. In an
additional approach of ARS in monkey treated with MSC
transfusion the one shown animal did not survive 12 days [34].
However, not many of the HSC cotransplanted animals survived
long-term either. Because of the low number of experimental
animals it remains to be determined if the cells (mean of 14.23%
of MSCs were positive for SH2) or the model were not optimal
for appropriate assessment. Taken together, our and results from
others [36] support the trophic effects of MSCs rather than
transdifferentiation.
In contrast to ‘‘conventional’’ MSCs described here, mesoder-
mally derived multipotent adult progenitor cells (MAPCs) with
their extraordinarily high plasticity are unable to radioprotect
lethally irradiated recipients but possess long-term multilineage
hematopoietic repopulating activity, thus preceding HSCs in
ontogeny [37,38]. However, their in vivo equivalent and the true
nature (e.g. in vitro artifact) are still unknown. MAPCs seem to
differ fundamentally from MSCs in their in vitro and in vivo
differentiation potential.
Kinetic analysis of the distribution of eGFP+ donor cells after
i.v. transplantation substantiated the fast disappearance from PB.
Figure 4. Donor mMSCs are not detectable long-term. (a)
Tracking of eGFP-labeled clonal IXH8 donor mMSCs after transplanta-
tion revealed a fast decrease in PB. Within 8 hours, approx. 2% were
quantified in PB and none after 10 days (n=8 for each time point).
Insert: mMSCs accumulated in lungs (Lu) within 24 h and disappeared
within 10 days (not shown). Spleen (Sp), liver (Li) and BM were negative
at d1. (b) Based on standard dilutions (filled symbols), no eGFP signals
(open symbols) above the assay’s detection limit of approx. 0.5% were
detected in the BM of long-term survivors reconstituted with mMSCs of
clone IXH8 (dashed line, detection limit of qPCR). nd, not detected.
doi:10.1371/journal.pone.0014486.g004
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term residence and embolization as revealed by lack of donor
signals 10 days post-transplant. Additionally, no homing of
donor mMSCs to the BM was evident, pointing to salvage of
endogenous irradiation-surviving HSCs but not to reconstitution
of hematopoiesis by donor MSCs. This conclusion is corrobo-
rated by the gene expression profile in BM of MSC-transplanted
animals. MSCs in a complex mechanism counteracted factors,
e.g. oxidative stress, inflammation and toxification by degrada-
tion products which suppress the recovery of remaining HSCs.
The MSC-mediated regulation of the niche environment likely is
a redundant system that is mediated by several molecules as has
been shown for immunoregulation by MSCs [18]. Irradiation
produces excessive inflammatory responses [39], contributing to
HSC death if left untreated. Among other organs, the lung is
especially sensitive towards irradiation damage and may retain
MSCs. MSCs interfere with inflammation by changing the gene
expression profile not only in the lungs where they dock [40] but
also in BM. To do so, MSCs need not necessarily home to the
B Mb u tm i g h tg l o b a l l yc h a n g eg e n ee x p r e s s i o no ra c t i v a t et h e
production of systemically counteracting substances. This
mechanism has been described for MSCs influencing myocar-
dial infarction [40]. Similarly to mMSCs, injected hMSCs
trapped in lungs and affect the production of the anti-
inflammatory protein TSG6 which enhances myocardial repair
without significant engraftment. Differentiation-independent
paracrine MSC-effects also ameliorate acute kidney injury via
anti-inflammatory, mitogenic and angiogenic actions [41,42].
Impressing clinical benefits of MSCs combining surgery and
local cellular therapy for the treatment of severe radiation burns
has been demonstrated. Uncontrolled clinical symptoms of
radiation inflammatory waves successfully could be limited
during patient’s 8-month follow-up as evidenced by the decrease
in the C-reactive protein level observed after each MSC
administration thus confirming modulating activity of MSCs in
inflammatory processes [43].
Secretion of a broad range of bioactive molecules which alter
the tissue microenvironment is now believed to be the main
mechanism by which MSCs achieve their therapeutic effect. The
transplanted MSCs might, as a principal mechanism, export their
inherent trophic effect to unorthodox sites [44]. The outcome is an
enhanced regeneration of injured cells, stimulation of proliferation
and differentiation of endogenous tissue progenitors, but also a
decrease in inflammatory and immune reactions [14].
Figure 5. Spectral karyotyping of mMSCs. (a) Shown is the SKY analysis of clone IXH8. SKY analysis revealed clonal structural and numerical
chromosomal alterations as demonstrated in the spectral image of a representative diploid metaphase. (b) In most metaphases, we observed a
hypertriploid (representative metaphase shown here) to an almost hypotetraploid chromosome complement with loss of the Y-chromosome in all
metaphases analyzed.
doi:10.1371/journal.pone.0014486.g005
Radiation Rescue with MSCs
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e14486Table 3. Differential gene expression in bone marrow of mice transplanted with HSCs or MSCs.
Accession No Gene Name Mean HSC Mean MSC ratio p-value
Suggested functions
[references]
Upregulated in MSCs
NM_010436 H2A histone family, member X (H2afx) 7.18 11.05 14.65 0.0076 DNA repair [1]
AF316872 protein kinase BRPK/PINK1 (Pten induced
putative kinase 1)
7.52 9.94 5.36 0.0082 Protection from oxydative stress
[2]
NM_007399 a disintegrin and metalloprotease
domain 10 (Adam10)
5.69 7.94 4.74 0.0097 shedding of inflammation driving
substrates [3,4]
NM_007669 cyclin-dependent kinase inhibitor 1A (P21)
(Cdkn1a)
10.19 12.42 4.68 0.0031 Cell cycle control [5]
NM_144530 zinc finger CCCH type containing 11A
(Zc3h11a)
9.03 11.09 4.18 0.0016 Signal transduction [6]
NM_020619 glucosidase 1 (Gcs1), mannosyl-
oligosaccharide glucosidase (Mogs)
6.29 8.29 4.00 0.0067 Reentry in the mitotic cell cycle,
actin cyto-skeletal organization
[7]
NM_008750 nucleoredoxin (Nxn) 6.14 7.93 3.46 0.0079 accelerated proliferation after
oxidative stress [8]
NM_011932 dual adaptor for phosphotyrosine and
3-phosphoinositides 1 (Dapp1), synonym
for BAM32
8.73 10.40 3.18 0.0055 lymphocyte proliferation [9,10]
NM_009201 solute carrier family 1, member 7 (Slc1a7) 9.33 11.00 3.18 0.0079 Na+-dependent amino acid
transporter [11]
NM_010110 ephrin B1 (Efnb1) 5.15 6.82 3.18 0.0063 angiogenic remodelling [12]
NM_011581 thrombospondin 2 (Thbs2) 6.02 7.65 3.10 0.0020 antiinflammatory [13]
AA116457 mp95d10.r1 Soares_thymus_2NbMT
cDNA clone IMAGE:576979 59
5.63 7.14 2.85 0.0089 unknown
AB017136 cupidin/HOMER 2, complete cds 6.36 7.83 2.77 0.0029 regulation of T-cell cytokine
production [14]
NM_010360 glutathione S-transferase, mu 5 (Gstm5) 11.15 12.54 2.62 0.0096 detoxification [15]
D85612 NFATx (NFAT4), complete cds 7.90 9.27 2.57 0.0046 Ca
2+ dependent T-cell activation
[16]
Downregulated in MSCs
AV277818 RIKEN full-length enriched, adult male
testis (DH5a) cDNA clone 4932701P08 39,
7.83 6.50 2.52 0.0094 unknown
NM_029303 profilin 3 (Pfn3), mRNA 6.67 5.30 2.58 0.0051 actin filament assembly (cell
motility) [17]
NM_172555 RIKEN cDNA 9630006B20 gene poly(A)
polymerase gamma (Papolg)
10.09 8.71 2.60 0.0018 Ion channel [18]
NM_007432 alkaline phosphatase 3, intestine, not Mn
requiring (Akp3)
6.15 4.74 2.65 0.0051 fat absorption [19]
NM_009080 ribosomal protein L26 (Rpl26) 12.03 10.60 2.70 0.0030 irradiation-induced apoptosis
[20]
NM_021301 solute carrier family 15 (H+/peptide
transporter), member 2 (Slc15a2)
10.39 8.95 2.70 0.0068 peptide transport [21]
AK020595 adult male urinary bladder cDNA, RIKEN
clone:9530043P15 product:hypothetical
Pancreatic ribonuclease
11.94 10.49 2.73 0.0098 RNase
BM240956 K0609H05-3 NIA Hematopoietic Stem
Cell (Lin2/c-Kit2/Sca-1+) cDNA clone
NIA:K060, Zfp850 (zinc finger protein 850)
9.67 8.17 2.83 0.0064 unknown
AK013872 12 days embryo head cDNA, RIKEN
clone:3000004N20 product:hypothetical
RNA-binding region RNP-1
10.03 8.47 2.95 0.0004 unknown
NM_011518 spleen tyrosine kinase (Syk) 11.86 10.29 2.96 0.0059 adhesion regulation [22]
BM119878 L0931F08-3 NIA Newborn Kidney cDNA
Library (Long) cDNA clone NIA:L0931F08
IMAGE:30003043 39
9.11 7.52 3.01 0.0083 unknown
NM_011774 solute carrier family 30 (zinc transporter),
member 4 (Slc30a4)
10.708 9.08 3.06 0.0052 enzyme activity [23]
NM_080595 EMI domain containing 1 (Emid1) 9.71 8.09 3.08 0.0034 ECM formation [24]
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mechanism working also in BM after lethal irradiation in mice.
MSCs, moreover, might be helpful in alleviating myelosuppression
due to chemotherapy and toxic drug reaction. Whether the results
can be translated to humans still has to be shown. Because BM-
derived MSCs are easily accessible, can be massively expanded,
and stored for prolonged time, they are easily distributed to places
in need. We suggest MSC-infusion as an efficient and immediate
treatment option after irradiation injuries.
Materials and Methods
Mouse MSC generation and characterization
Ethics Statement: Animal experiments were approved by the
local ethical committee (License Department Hamburg) under
application No. 64/02 and 84/05 and performed according to
their guidelines.
Female C57BL/6J-CD45.1 mice (The Jackson Laboratory)
represented the recipient population, male C57BL/6J mice with
the wild-type CD45 (CD45.2) were used as donor animals.
Mouse MSCs were isolated from male bone marrow and
expanded for 9 passages in DMEM/Ham’s F12 medium
(Biochrom) supplemented with 20% preselected fetal calf serum
and 2mM glutamine (both: Invitrogen). The cells were retrovirally
labeled with SF91-eGFP [45] at MOI=3 (bulk population) and
expanded or seeded for cloning into ten 96-well plates at 0.3 cells/
well. Expanded bulk and selected clonal mMSCs of P14–P18 were
characterized according to their differentiation capability into
adipo-, chondro- and osteogenic lineages and phenotype as
described [46] according to ISCT criteria [17].
Accession No Gene Name Mean HSC Mean MSC ratio p-value
Suggested functions
[references]
BB078651 RIKEN full-length enriched, adult male
diencephalon cDNA clone 9330154I19 39
6.99 5.365 3.10 0.0066 unknown
NM_172734 serine/threonine kinase 38 like (Stk38l) 9.33 7.61 3.30 0.0090 neural differentiation [25]
NM_011261 reelin (Reln) 11.03 9.25 3.44 0.0041 neural differentiation [26]
NM_018800 synaptotagmin 6 (Syt6) 7.18 5.39 3.47 0.0021 vesicular transport proteins [27]
AK006217 adult male testis cDNA, RIKEN
clone:1700021K19 product:hypothetical
Serine-rich region/Cysteine-rich
11.07 9.19 3.70 0.0099 unknown
BB713538 RIKEN full-length enriched, 2 cells egg cDNA
clone B020047L15 39, mRNA sequence
8.82 6.90 3.79 0.0041 unknown
AK005904 adult male testis cDNA, RIKEN
clone:1700012G05 product:RIKEN cDNA
1700012G05 gene
12.91 10.95 3.88 0.0044 unknown
NM_013911 F-box and leucine-rich repeat protein 12
(Fbxl12)
11.07 9.03 4.11 0.0098 ubiquitin-mediated proteolysis
[28]
NM_009020 recombination activating gene 2 (Rag2) 10.72 8.61 4.31 0.0032 lymphoid development [29]
BC037381 3-hydroxymethyl-3-methylglutaryl-
Coenzyme A lyase-like 1 (HMDC)
10.15 7.98 4.48 0.0095 phospholipid biosynthesis
NM_011838 Ly6/neurotoxin 1 (Lynx1) 8.81 6.48 5.01 0.0091 cell development [30]
NM_016919 collagen, type V, alpha 3 (Col5a3), mRNA 10.12 7.69 5.39 0.0072 Structure of fibrillar collagen [31]
AK013322 10, 11 days embryo whole body cDNA,
RIKEN clone: 2810450N13 product:
hypothetical Formamidopyrimidine-DNA
glycolase containing protein/ NEIL1
11.33 8.86 5.53 0.0041 DNA repair after oxydative
damage[32]
NM_008456 kallikrein 1-related peptidase b5 (Klk1b5) 8.95 6.47 5.58 0.00006 ECM proteolysis, pro-
inflammation [33]
NM_008149 glycerol-3-phosphate acyltransferase,
mitochondrial (Gpam)
10.94 8.40 5.80 0.0035 glycerolipid synthesis [34]
NM_010639.5 kallikrein 6 (Klk6) 8.67 5.84 7.13 0.0029 ECM proteolysis, pro-
inflammation [33]
NM_011670 ubiquitin carboxy-terminal hydrolase L1
(Uchl1)
10.15 5.94 18.52 0.0008 Protein degradation [35]
BC037993 smoothelin-like 2 (Smtnl2) 11.12 6.41 26.10 0.0031 Actin stress fibers, inhibition of
vasodilation
AK007907 10 day old male pancreas cDNA, RIKEN
clone:1810059H22 product:hypothetical
protein
12.27 6.66 49.02 0.0024 unknown
NM_016982 pre-B lymphocyte gene 1 (Vpreb1) 14.41 8.25 71.59 0.0030 B cell development [36]
Mean gene expression levels from microarray analysis in bone marrow at d21 after transplantation were calculated for 2 arrays per group hybridized with RNA from
pooled BM (HSC: 2 animals/array, MSC: 3 animals/array). Selected were genes with p#0.01 after t-test filtering and ratio of $2.5 or #2.5. References for suggested
functions were selected in the context of cell functionality after transplantation and are shown in Text S1.
doi:10.1371/journal.pone.0014486.t003
Table 3. Cont.
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was carried out as described via LM-PCR [45]. Genomic DNA
was digested with Tsp509I giving rise to integration specific
fragments of unique lengths. Linker cassettes with known
sequences were ligated to the restriction sites. Primer were
designed to bind at the known sequences of the provirus and the
linker cassette. Amplified PCR products were loaded onto the gel.
After gel extraction the bands (red stars) were sequenced. Using
the BLAST algorithm, the obtained sequences were aligned to the
mouse genome to identify the integration sites.
Chromosome preparation and spectral karyotyping of eGFP-
transduced bulk-mMSCs, passage 13 and clone IXH8, passage 20
were performed as described [47].
Mouse MSC transplantation
TBI was performed using a Cs-137 radiation source. Lethally
(9.5 Gy) irradiated female C57BL/6J-CD45.1 mice were i.v.
transplanted within 8 hours with 10
6 cells divided into following
groups: (i) male bulk (n=28) or cloned (n=59; irradiation
controls n=15) mMSCs of P15–P20 for investigation of long-term
survival; (ii) clone IXH8 mMSCs (n=32) to investigate the in vivo
distribution of donor mMSCs; (iii) BM (n=4, named HSC) or
bulk mMSCs (n=6, named MSC) for microarray analysis; (iv)
HSC (n=10) or bulk mMSCs (n=9) to validate the differential
gene expressions obtained with the microarray.
Sample acquisition and examination
Fromexperimentalanimals ofgroup(i) blood samples weretaken
retroorbitally and cell counts analyzed using a Coulter Onyx. Seven
months later, PB, BM, thymus, lymph node, liver, spleen, lung,
intestine, aorta/vena cava and abdominal fat were removed and
usedforgenomicdetection oftheY-chromosome(Sry)and/oreGFP
via quantitative PCR (Table S2). Parts of lung tissues were fixed in
formalin, paraffin embedded and serial cuts stained with HE, von-
Kossa stain visualizing calcium precipitates and Collagen I.
Genomic DNA from PB and BM was isolated the same day
using innuPREP Blood DNA Mini kit (analytikjena), DNA from
all other snap frozen organs with Invisorb Spin Tissue Mini Kit
(Invitek). To yield a standard curve, male/GFP-positive DNA was
diluted at decreasing concentrations in female/GFP-negative
DNA. Quantitative PCR reactions were performed on a
Mx3000P (Stratagene). Reaction mixture contained 50 ng of
DNA, SYBR Premix Ex Taq (Takara Bio INC), and 200 nM
primers (MWG-BIOTECH AG). The threshold cycle (Ct) was
determined for each reaction by the MxPro Software. Amplifica-
tion efficiency was calculated by the sliding window method
(LinReg software)[48]. Normalization of expression values was
done using Rps27a for eGFP and control chro11 for Y-chromosome
tests. Additionally, parts of freshly isolated PB, BM and thymus
were investigated for donor derived eGFP- and CD45.2-antigen-
expression using flow cytometry as described [45].
Blood samples from animals of group (ii) were taken at different
time points (20 min, 2, 4, 8, 12 and 24 hours; n=8 for each time
point) after transplantation and isolated DNA used for Sry/eGFP-
chromosomal quantitative PCR. At day 1 and 10, PB, BM, lung,
liver and spleen were obtained for DNA isolation. All samples
were quantitatively tested for a) the Y-chromosome of recipient
cells and b) the stably integrated eGFP.
Figure 6. Transplantation of mMSCs leads to gene expression changes in BM supporting rescue of endogenous hematopoiesis. (a)
Bootstrap hierarchical clustering of all 20K genes depicted highly stable clusters for HSC/BM vs. MSC. (b) Heat map clustering using average distance
and Manhattan metric for 2 microarrays per group hybridized with RNA from pooled BM (HSC: 2 animals/array, MSC: 3 animals/array) is shown for
genes summarized in Table 3. (c) Gene expression ratios of selected genes using BM of mice 21 days after transplantation with MSCs (n=9) or HSCs
(n=10) were investigated for independent cohorts (grey columns: microarray data; white columns: quantitative PCR). Shown are mean ratios 6 SEM.
P,0.005. Suggested functions of validated genes are shown in italics.
doi:10.1371/journal.pone.0014486.g006
Figure 7. Ectopic ossicles in mice lungs after i.v. transplantation of bulk mMSCs. Mice subjected to total body irradiation and transplanted
i.v. with syngeneic MSCs were analyzed after 7 months. In lungs, fibrotic lesions were detected with HE staining (a) which showed the typical dark
precipitates in von-Kossa stainings (b) admixed with large Collagen I-positive areas (c) suggesting bone and cartilage containing ossicles.
doi:10.1371/journal.pone.0014486.g007
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HSC- and mMSC-transplanted groups was flushed combining the
cells of 2 or 3 mice respectively and used for RNA isolation using
Invisorb Spin Cell RNA Mini Kit (Invitek). Non-manipulated BM
of age-matched mice (n=4, named BM) was used as control.
Differential gene expression was investigated using CodeLink
UniSet Mouse 20K I Bioarrays as described previously [46]. For
each group (BM, HSC, MSC), two arrays were hybridized. Gene
expression profiles of all genes were grouped by hierarchical
clustering (TIGR MeV v.4.5.1; Manhattan distance, average
linkage). All data is MIAME compliant and the raw and processed
data has been deposited in a MIAME compliant database at the
gene expression omnibus (GEO) under accession GSE21867.
Validation of differential gene expression of genes with a fold
change of $2.5 was done on the independent mouse group (iv)
using d21 BM of 10 animals transplanted with HSCs and 9
animals transplanted with clonal IXH8 mMSCs. Primers used are
listed in Table S2. Differences in gene expressions in BM of MSC
and HSC transplanted animals were determined based on the
DDCt method normalized for Taf12 and Rps27a.
Statistical analysis
For statistical analysis, unpaired and two-tailed Student’s t-test
was applied. P-values ,0.05 were considered statistically signifi-
cant.
Supporting Information
Figure S1 In vitro differentiated human MSCs express hema-
topoietic and endothelial genes and proteins. In vitro differentiated
human MSCs express hematopoietic and endothelial genes and
proteins. Use of human bone marrow for research was approved
by the Ethical Committee of Hamburg. All experiments have been
conducted according to the principles of the Declaration of
Helsinki. After written informed consent, BM-derived human
MSCs (hMSCs) were cloned and expanded in DMEM/LG+10%
preselected FCS. Hematopoietic predifferentiation was carried out
in serum-containing (HC1) conditions using IMDM+10%
FCS+10% horse serum +1026 M hydrocortisone, mixed 1:1
with MethoCult H4434 (containing SCF, GM-CSF, IL-3, and
Epo) for 2 weeks followed by differentiation for 2 weeks in
MethoCult H4435 (containing SCF, GM-CSF, IL-3, IL-6, G-CSF
and Epo). A 2-week serum-free (HC2) predifferentiation consisted
of StemSpan+SCF+flt3-ligand+TPO+GM-CSF+Epo followed by
a 2-week differentiation in MethoCult H4436 (containing SCF,
GM-CSF, IL-3, IL-6, G-CSF and Epo). For endothelial
differentiation (EC), hMSCs were seeded in fibronectin-coated
wells in serum-free StemSpan supplemented with SCF, flt3-ligand,
TPO, and Epo for a 2-week prestimulation, followed by a 2-weeks
stimulation with StemSpan supplemented with VEGF, FGF-2,
IGF, and insulin. Comparative gene expression was tested with
qPCR before and after differentiation and normalized to GAPDH
and RPS27A. Proteins were detected immunocytochemically on
cytospins. (A) Out of 5 clones, IVF1 showed upregulated
expression of genes characteristic for early (CD117, CD133,
CD41, CD45, EPOR) and mature (CD14, CD16, GlyA, CD31,
PDPN) hematopoietic cells as well as several myeloid-lineage
transcription factors (GATA1, GATA2, GATA3, RUNX1,
NOTCH1, SCL). This upregulation was particularly detected
under HC1 (black columns) but also to some extent under HC2
(light grey columns) conditions. Stimulation of endothelial
differentiation resulted in gene upregulation of primarily CD31
and KDR (lower part of (a) in dark grey). (B) In concordance with
increased gene expression, immunocytochemistry demonstrated
expression of early and late hematopoietic (HC1 differentiation
shown in the left, HC2 in the middle column) as well as endothelial
(EC, right column) antigens as indicated. Either single or, where
available, clusters of positive cells are shown. On most cytospins,
only single positive cells for the respective antigen were detected.
In EC, yellow indicates positivity for both antigens analyzed. All
cytospins were counterstained with DAPI to visualize nuclei. The
lower part of the right column (‘‘clusters’’) shows typical examples
of closely clustered dissociation-resistant cells. The most efficient
differentiation of hMSCs was obtained when either MSCs (upper
picture, white arrows) or already differentiated megakaryocytes
(lower picture, white arrow) provided the differentiation environ-
ment mimicking the stromal compartment structure in vitro.
Human MSCs positive for hematopoietic or endothelial antigens
after differentiation decreased cell size from 28.9+/26.6 to 15.7+/
23.5 mm as well as size and shape of nuclei. Original
magnification 6400. Abbreviations: GlyA, glycophorin A; EPOR,
erythropoietin receptor; PDPN, podoplanin; VWF, von Will-
ebrand factor; KDR, Kinase insert domain receptor, also referred
to as VEGFR2 or FLK1; nd, not detected. Bar: 10mm.
Found at: doi:10.1371/journal.pone.0014486.s001 (0.55 MB TIF)
Table S1 Characterization of mMSC clones with LM-PCR. For
each clone, the analyzed bands demonstrating the integration sites
are shown. Column ‘‘position to Transcription Start Site’’
describes the location of the provirus: ‘‘+’’ means the provirus is
located 39- to the transcriptional start site of the listed gene, ‘‘2’’
means the provirus is located 59- the transcriptional start site of the
listed gene. Adjacent genes of the integration sites were
determined in a window of 200kb. Column ‘‘orientation’’ shows
the orientation of the provirus with regard to the listed gene.
Found at: doi:10.1371/journal.pone.0014486.s002 (0.10 MB
DOC)
Table S2 Sequences of primers used for quantitative PCR.
Found at: doi:10.1371/journal.pone.0014486.s003 (0.05 MB
DOC)
Text S1 Supplementary Text to Table 3. References cited in
Table 3 are selected in the context of cell functionality after
transplantation.
Found at: doi:10.1371/journal.pone.0014486.s004 (0.04 MB
DOC)
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